GWA
PBE icon

Genesis Wealth Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Genesis Wealth Advisors’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		$17.5K Hold
300
– – 0.01% 296
2015
Q1 		$16.6K Hold
300
– – 0.01% 305
2014
Q4 		$16.6K Buy
+300
New +$14.7K 0.01% 331

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TAM
Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return
QA
Quantitative Advantage Minnetonka, Minnesota $689M AUM 6.25% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $1.7B AUM 39.15% 1-Year Est. Return

Genesis Wealth Advisors's PBE Position: Q2 2015 in Review

Genesis Wealth Advisors held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q2 2015 at 300 shares worth $17.5K. The position accounts for 0.01% of the portfolio, ranked #296.

Genesis Wealth Advisors first reported a position in PBE in Q4 2014 and has held it in 3 quarters since. 86 funds tracked by Wall St. Rank hold PBE as of Q2 2015.

  • Genesis Wealth Advisors held 300 shares of Invesco Biotechnology & Genome ETF worth $17.5K as of Q2 2015.
  • Genesis Wealth Advisors left its Invesco Biotechnology & Genome ETF share count unchanged in Q2 2015.
  • Invesco Biotechnology & Genome ETF made up 0.01% of Genesis Wealth Advisors's portfolio in Q2 2015, its #296 holding.
  • Genesis Wealth Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q4 2014 and has held it in 3 quarters since.
  • 86 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2015.

Based on Genesis Wealth Advisors's 13F filing for Q2 2015, filed 24 Aug 2015.